GeneDx Holdings Corp. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Reported first quarter 2024 revenue from continuing operations 1 of $61.5m with 96% year-over-year growth of exome and genome test revenue expanded first quarter 2024 adjusted gross margins 2 from continuing operations to 61% narrowed first quarter 2024 adjusted net loss 2 to $8.5m and delivered 71% year-over-year cash burn reduction raised guidance to deliver between $235m and $245m in fy 2024 revenue and reiterate path to profitability in 2025 genedx to host conference call today at 4:30 p.m. et stamford, conn.

The company will also participate in a world orphan drug congress panel presentation highlighting the role of genomic sequencing in advancing precision medicine the company will also participate in a world orphan drug congress panel presentation highlighting the role of genomic sequencing in advancing precision medicine

Management will host a conference call on monday, april 29, 2024 to discuss first quarter 2024 financial and operating results at 4:30 p.m. eastern time.

Stamford, conn., march 14, 2024 (globe newswire) -- genedx (nasdaq: wgs), a leader in delivering improved health outcomes through genomic insights, today announced its scientific contributions at the 2024 american college of medical genetics and genomics (acmg) annual clinical genetics meeting. across one platform presentation, an industry symposium and six poster presentations, including one selected as a “rapid fire poster session,” an invitation-only presentation of the top 20 acmg posters, genedx continues to demonstrate its industry leadership in shaping the future landscape of genomics.

Stamford, conn., feb. 26, 2024 (globe newswire) -- genedx (nasdaq: wgs), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company management will participate in the cowen healthcare conference from march 4-6 in boston, ma.

GeneDx Holdings Corp. (NASDAQ:WGS ) Q1 2024 Earnings Conference Call April 29, 2024 4:30 PM ET Company Participants Sabrina Dunbar - Commercial Chief of Staff Katherine Stueland - President and Chief Executive Officer Kevin Feeley - Chief Financial Officer Conference Call Participants Daniel Brennan - TD Cowen Mark Massaro - BTIG, LLC Matthew Sykes - Goldman Sachs Matthew Stanton - Jefferies Group LLC Operator Ladies and gentlemen, thank you for standing by, and welcome to the GeneDx First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

GeneDx Holdings Corp. (WGS) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $2.82 per share a year ago.

Management will host a conference call on Monday, April 29, 2024 to discuss first quarter 2024 financial and operating results at 4:30 p.m. Eastern Time.

GENEDX HOLDINGS (WGS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

STAMFORD, Conn., March 14, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced its scientific contributions at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting. Across one platform presentation, an industry symposium and six poster presentations, including one selected as a “Rapid Fire Poster Session,” an invitation-only presentation of the top 20 ACMG posters, GeneDx continues to demonstrate its industry leadership in shaping the future landscape of genomics.

GeneDx Holdings Corp. (WGS) Q4 2023 Earnings Call Transcript

GeneDx management will host a conference call at 4:30 p.m. Eastern Time on February 20, 2024 to discuss 2023 results and share full year 2024 guidance.

GeneDx Holdings Corp shares jumped 21% to $4.68 in late-morning trading on Tuesday after the provider of exome and genome testing and interpretation announced that it expects to exceed revised 2023 revenue guidance with fourth quarter 2023 revenue from continuing operations of more than $57 million.   GeneDx also said it expects at least 63% year-over-year growth from its exome and genome test revenue.

After losing some value lately, a hammer chart pattern has been formed for GeneDx Holdings Corp. (WGS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

GeneDx Holdings Corp. (NASDAQ:WGS ) Q3 2023 Results Conference Call October 30, 2023 4:30 PM ET Company Participants Sabrina Dunbar - Chief of Staff Katherine Stueland - President and CEO Kevin Feeley - CFO Conference Call Participants Joe Flanagan - Cowen Mark Massaro - BTIG Matt Kim - Jefferies Prashant Kota - Goldman Sachs Operator Good day, and thank you for standing by. Welcome to the GeneDx Third Quarter 2023 Earnings Conference Call.